Search clinical trials for: Insulin analogs (Lispro and Aspart)

Total 4421 results

Novo Nordisk A/S

Completed

A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus (BEGIN™)

Diabetes | Diabetes Mellitus, Type 1

Germany, France, United States, Japan, Netherlands, Russian Federation, Bulgaria, United Kingdom, North Macedonia, South Africa, Italy, Finland
Novo Nordisk A/S

Completed

A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes (SWITCH 1)

Diabetes | Diabetes Mellitus, Type 1

United States, Poland, Puerto Rico
Eli Lilly and Company

Completed

Comparison of Two Approaches to Insulin Therapy in Patients With Type 2 Diabetes (IOOX) (IOOX)

Diabetes Mellitus, Type 2

Australia, Russian Federation, Spain, Mexico, Canada, France, Korea, Republic of
University of California, San Diego
The Leona M. and Harry B. Helmsley Charitable Trust

Not yet recruiting

Suppression of Endogenous Glucose Production by Injectable HDV-Insulin Lispro: A Dose Response Study in Human Subjects With Type 1 Diabetes

Type 1 Diabetes
Novo Nordisk A/S

Completed

Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

United States, Sweden, Norway, Germany, Australia
Novo Nordisk A/S

Completed

Self-control Trial to Evaluate the Remission Rate in Newly Diagnosed Type 2 Diabetes Patients After Treatment With Insulin Aspart

Diabetes Mellitus, Type 2 | Diabetes

China
Munich Municipal Hospital
Novo Nordisk A/S

Unknown

Insulin Effects on Metabolism and Cardiovascular Function in Type 2 Diabetes

Type 2 Diabetes Mellitus

Germany
Profil Institut für Stoffwechselforschung GmbH
Novo Nordisk A/S

Completed

Metabolic Effect of Insulin Aspart and Human Insulin in Different Doses

Diabetes Mellitus

Germany
Massachusetts General Hospital

Completed

The Insulin-Only Bionic Pancreas Bridging Study

Type1 Diabetes Mellitus

United States
Defymed

Recruiting

Pilot Study Evaluating Safety of ExOlin® in Patients With Poorly Controlled Type 1 Diabetes (Pilot'Ex)

Type 1 Diabetes | Type 1 Diabetes Mellitus With Hypoglycemia

France
Novo Nordisk A/S

Completed

A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)

Diabetes Mellitus, Type 2

India, United States, Thailand, Japan, Germany, Turkey, Hungary, Malaysia, Poland, South Africa, Czechia, Italy, France, Slovenia
Rush University Medical Center
Novo Nordisk A/S

Completed

Subcutaneous Aspart Insulin to Treat Diabetic Ketoacidosis (DKA) and Beta-Hydroxybutyrate Testing in DKA (DKA)

Diabetic Ketoacidosis

United States
Eli Lilly and Company

Completed

Effects of Insulin in Perceived Mood Symptoms in Patients With Type 2 Diabetes

Type 2 Diabetes

United States
Perosphere Pharmaceuticals Inc, a wholly owned...
Profil Institut für Stoffwechselforschung GmbH

Withdrawn

Pharmacokinetics of Ultra-Rapid-Acting Insulin Lispro (URAL) in Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

Germany
Novo Nordisk A/S

Completed

Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Canada, Puerto Rico
Novo Nordisk A/S

Completed

Bioequivalence Between Two Explorative Insulin Degludec Formulations and Between Two Explorative IDegAsp Formulations in Healthy Subjects

Healthy | Diabetes

Germany
Mount Sinai Hospital, Canada
Canadian Institutes of Health Research (CIHR)

Completed

Early Intermittent Intensive Insulin Therapy as an Effective Treatment of Type 2 Diabetes (RESET-IT Pilot Study)

Type 2 Diabetes

Canada
Novo Nordisk A/S

Completed

Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

United States, United Kingdom, France, Netherlands, Finland, Germany, Sweden
Sanofi

Completed

Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents

Diabetes Mellitus, Insulin-Dependent

United States
Novo Nordisk A/S

Completed

Effects of Biphasic Insulin Aspart 70/30 vs. Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea.

Diabetes Mellitus, Type 2 | Diabetes

United States
Diasome Pharmaceuticlas, Inc.

Recruiting

Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec (OPTI-2)

Diabetes Mellitus, Type 1

United States
Novo Nordisk A/S

Completed

A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes (SUSTAIN 11)

Diabetes Mellitus, Type 2

Croatia, India, Poland, Spain, Serbia, Germany, Slovakia, Slovenia, Turkey, Hungary, Greece, Czechia, Bulgaria, South Africa, Romania, Bosnia and Herzegovina, Estonia, Portugal, Latvia, Lithuania, North Macedonia
Novo Nordisk A/S

Completed

Comparison of Efficacy and Safety of Insulin Detemir and Insulin Glargine in Patients With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany, Austria, South Africa
Novo Nordisk A/S

Completed

Comparison of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Sweden, Finland, France, Norway
Novo Nordisk A/S

Completed

An Indian Post Marketing Study of Mealtime Insulin, Fiasp®, to Evaluate Its Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1

India
Novo Nordisk A/S

Completed

A Trial Comparing the Pharmacokinetic Properties of Faster-acting Insulin Aspart (FIAsp) After Different Injection Regions and Routes of Administration in Healthy Subjects

Healthy | Diabetes

Germany
Novo Nordisk A/S

Completed

Observational Study of Type 1 Diabetics Switching From Human Insulins to Modern Insulin Analogues

Diabetes | Diabetes Mellitus, Type 1

Romania
Adocia

Completed

A Trial to Investigate Post Prandial Blood Glucose Control With Fast-acting Human Insulin HinsBet® Compared to Insulin Lispro (Humalog®) and Regular Human Insulin (Huminsulin® Normal) After Ingestion of a Standardized Meal in Subjects With T1DM

Type 1 Diabetes Mellitus

Germany
University Health Network, Toronto

Completed

Regulation of Endogenous Glucose Production by Brain Insulin Action (Nasal insulin)

Insulin Resistance, Diabetes

Canada
Eli Lilly and Company

Completed

Lispro Mix 25 vs. Glargine in Type 2 Diabetics (IOOL)

Diabetes Mellitus Type 2

Mexico
Novo Nordisk A/S

Completed

Examining the Long-term Safety of Insulin Aspart When Used as a Part of the Treatment for Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Russian Federation, Israel, Croatia, Czech Republic, Slovenia
Novo Nordisk A/S

Terminated

Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

United States, Canada
The Cleveland Clinic
Novo Nordisk A/S

Completed

Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With Type-2 Diabetes Mellitus (TRANSITION-T2D)

Type 2 Diabetes

United States
Novo Nordisk A/S

Completed

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0143-0406 A 0.6 mmol/L in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Austria
Novo Nordisk A/S

Completed

Comparison of Two Insulin Aspart Formulations in Healthy Volunteers

Healthy | Diabetes

South Africa
ikfe-CRO GmbH
IKFE Institute for Clinical Research and Development

Unknown

Human Insulin Analogs: Evaluation of Inflammatory mRNA Expression of Macrophages and Endothelial Function of Short-acting Insulin - HERMES Pilot Study (HERMES)

Type 2 Diabetes Mellitus

Germany
Sanofi

Completed

Lantus Versus Humalog Mix as add-on Therapy in Type Diabetes Patients Failing Sulfonylurea and Metformin Combination Treatment

Diabetes Mellitus, Type 2

United States
Novo Nordisk A/S

Completed

Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Characteristics of Explorative Formulations of Insulin Degludec and IDegAsp 50 in Healthy Japanese Subjects

Healthy | Diabetes

Germany
Medical University of Warsaw

Completed

Insulin Glulisine and Aspart in Postprandial Glycemic Control After High-GI Meal in Children With Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

Poland
Novo Nordisk A/S

Completed

Human Insulin NPH and Insulin Aspart in Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Argentina
Novo Nordisk A/S

Completed

Safety and Efficacy of Insulin Aspart vs. Regular Human Insulin in Gestational Diabetes

Diabetes | Gestational Diabetes

United States
Eli Lilly and Company

Completed

A Study of Basal Insulin Analog and Insulin Analog Mid Mixture in Chinese Participants With Type 2 Diabetes Mellitus (CLASSIC)

Type 2 Diabetes Mellitus

China
Mount Sinai Hospital, Canada
Canadian Institutes of Health Research (CIHR)

Completed

Early Intermittent Intensive Insulin Therapy as an Effective Treatment of Type 2 Diabetes (RESET-IT Main Trial) (RESET-IT)

Type 2 Diabetes

Canada
Novo Nordisk A/S

Terminated

Effect of Insulin Detemir on Use of Energy in Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

United Kingdom
Stanford University
University of Colorado, Denver; Biodel

Withdrawn

A Randomized Control Trial Comparing Linjeta Versus Humalog in Pumps: Effect on Postprandial Blood Sugars.

Diabetes Mellitus

United States
Novo Nordisk A/S

Terminated

Safety of Inhaled Preprandial Human Insulin in Subjects With Diabetes and Asthma (iINHALE 9)

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1 | Asthma

United States, Slovakia, India, Malaysia, Australia, Former Serbia and Montenegro
Beijing Hospital

Unknown

Comparing the Efficacy and Safety Between Short-term Continuous Subcutaneous Beinaglutide Injection and Continuous Subcutaneous Insulin Infusion (CSII) for Newly Diagnosed Type 2 Diabetes

Type 2 Diabetic Patients

China
Joslin Diabetes Center
Boston Children's Hospital

Completed

Insulin Bolus Required for High Fat Foods in Type 1 Diabetes

Type 1 Diabetes
Novo Nordisk A/S

Completed

Long Term Safety Trial to Compare Insulin Treatment With Preprandial Inhaled Human Insulin to s.c. Insulin Aspart Both Combined With NPH in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Australia
Gan and Lee Pharmaceuticals, USA

Withdrawn

Gan & Lee Evaluation of New Biosimilar for Type 1 Lispro (GENTL 1)

Diabetes Mellitus, Type 1

United States, Spain, Hungary, Poland, Germany, Czechia

3

Subscribe